{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-294328","form_type":"8-K","ticker":"VIR","cik":"0001706431","company_name":"Vir Biotechnology, Inc.","filed_at":"2023-12-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.119472+00:00","generated_at":"2026-06-07T13:32:21.617711+00:00","sec_items":["2.05"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Vir Biotechnology to cut 12% of workforce, close R&D sites; charges $30-40M","bullets":["Workforce reduction of ~75 positions (12%) and closure of St. Louis and Portland R&D facilities in 2024.","Estimated pre-tax charges of $30-40M, primarily facility-related; $3-4M cash expenditures. Annual savings at least $40M.","Company to focus on chronic hepatitis delta/B programs and expand monoclonal antibody platform into autoimmune and oncology.","Research to continue at San Francisco and Bellinzona sites.","Cash, equivalents, and investments of $1.7B as of Q3 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-294328","json":"https://secwatch.observer/filing/0001193125-23-294328.json","markdown":"https://secwatch.observer/filing/0001193125-23-294328.md","text":"https://secwatch.observer/filing/0001193125-23-294328.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/0001193125-23-294328-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/d643902d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T13:32:21.617711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7552c018f86188c646979d36ea29fa5c74ef3fa2","claim":"Vir Biotechnology, Inc. announced a restructuring with charges of $30 million to $40 million affecting research and development facilities (approximately 12% of the workforce or 75 positions).","evidence_excerpt":"continue at the Company’s sites in San Francisco, California and Bellinzona, Switzerland. As a result of these changes, the Company estimates that it will incur charges between $30 million to $40 million, primarily related to facility closures and to a lesser extent, employee severance costs. Of the total charges, the Company estimates that $3 million to $4 million","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1706431/000119312523294328/0001193125-23-294328-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"$30 million to $40 million"},{"label":"Affected area","value":"research and development facilities"},{"label":"Headcount","value":"approximately 12% of the workforce or 75 positions"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}